비교리스트

 카트 문의
시장보고서
상품코드
1559666

세계의 남성 성선 기능 저하증 시장

Male Hypogonadism
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 197 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

남성 성선기능저하증 세계 시장은 2030년까지 61억 달러에 이를 전망

2023년에 43억 달러로 추정되는 남성 성선기능저하증 세계 시장은 분석 기간 2023-2030년에 CAGR 5.0%로 성장하고, 2030년에는 61억 달러에 달할 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 테스토스테론 보충 요법은 CAGR 4.9%로 성장을 지속하고, 분석 기간 종료 시 35억 달러에 달할 것으로 예측됩니다. 성선 자극 호르몬 및 방출 호르몬 치료 분야의 성장률은 분석 기간 동안 CAGR 5.3%로 추정됩니다.

미국 시장은 12억 달러로 추정, 중국은 CAGR 4.8%로 성장 예측

미국 남성 성선기능저하증 시장은 2023년 12억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 분석 기간 2023-2030년의 CAGR 4.8%를 견인해 2030년에는 예측 시장 규모 9억 6,250만 달러에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 4.5%와 4.3%로 예측되고 있습니다. 유럽에서는 독일이 CAGR 5.0%로 성장할 것으로 예측됩니다.

세계 남성 성선 기능 저하증 시장 - 주요 동향 및 촉진요인 요약

남성 성선 기능 저하증은 무엇이며 왜 조기 진단이 중요한가?

남성 성선 기능 저하증은 테스토스테론 수치의 감소를 특징으로하는 병리학이며, 성욕 감퇴, 피로, 근력 저하, 기분 장애 등 다양한 증상을 유발합니다. 이 병태는 노화, 유전적 요인 또는 고환과 뇌하수체에 영향을 미치는 병리로 인해 발생할 수 있습니다. 남성 성선 기능 저하증의 조기 진단은 증상을 관리하고 골다공증, 심혈관 질환, 불임과 같은 장기 합병증을 예방하는 데 필수적입니다. 세계의 노화와 남성 호르몬 균형의 혼란에 대한 의식이 높아짐에 따라 효과적인 치료 및 진단 도구에 대한 수요가 크게 증가하고 있으며, 성선 기능 저하증의 조기 발견과 적절한 관리의 중요성이 부각되어 있습니다.

호르몬 대체 요법의 진보는 남성 성선 기능 저하증 치료를 어떻게 형성합니까?

남성 성선 기능 저하증의 치료는 테스토스테론 수치를 건강한 범위로 회복시키는 호르몬 대체 요법(HRT)의 개발로 크게 발전했습니다. 테스토스테론 보충 요법(TRT)은 젤, 주사, 패치 등 다양한 형태로 이용할 수 있으며 성선 기능 저하증의 치료가 필요합니다. 이러한 치료법은 증상을 완화할 뿐만 아니라 테스토스테론 결핍과 관련된 장기 건강 문제의 위험을 줄이는 데에도 도움이 됩니다. 투여 횟수가 적은 새로운 장시간 작용형 제제는 그 편리성과 안정한 테스토스테론 수준을 유지하는 능력으로 인기를 끌고 있습니다. 게다가, 개인화된 의료의 진보는 의료 서비스 제공업체가 개인의 필요에 맞게 치료를 할 수 있게 되어 환자의 결과와 만족도를 향상시킵니다.

남성 성선 기능 저하증의 관리에는 어떤 문제가 있는가?

남성 성선 기능 저하증의 치료에는 특히 환자가 적절하고 적시에 치료를받을 수있게하는 몇 가지 과제가 있습니다. 과제 중 하나는 많은 남성들이 테스토스테론 결핍 증상을 노화 때문으로 보고 의사의 진찰을 받지 않기 때문에 이 질병이 과소 진단되고 있다는 것입니다. 또한, 심혈관 사건의 위험 증가와 전립선 문제와 같은 장기적인 테스토스테론 요법의 잠재적인 부작용은 환자와 임상의의 양쪽에 우려를 야기합니다. 이러한 위험에 대해서는 신중한 모니터링과 개별 치료 계획이 필요합니다. 테스토스테론 보충 요법은 고액이며 보험 적용도 다양하므로 치료에 액세스하는 데도 어려움이 있습니다. 게다가, 치료에 대한 어드히어런스는 특히 치료를 정기적으로 수행할 필요성 때문에 여전히 우려 사항입니다.

남성 성선 기능 저하증 시장의 성장은 여러 요인에 의해 초래됩니다.

남성 성선 기능 저하증 시장의 성장은 노화로 인한 유병률 증가, 남성 호르몬 건강에 대한 의식 증가, 테스토스테론 보충 요법의 발전 등 여러 요인에 의해 견인되고 있습니다. 진단 도구가 개선됨에 따라 더 많은 남성이 조기에 진단되고 효과적인 치료에 대한 수요가 증가하고 있습니다. 장시간 작용하는 주사제 및 경피 패치와 같은 약물 전달 시스템의 기술 혁신은 환자의 컴플라이언스와 치료 성적을 향상시킵니다. 또한 남성의 건강에 대한 관심 증가와 원격 의료 서비스의 가용성 증가는 환자가 진단과 치료를 받기 쉽고 시장 확대에 기여하고 있습니다.

조사 대상 기업 예(주목의 47사)

  • Bayer AG
  • TesoRx Pharma LLC

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 기타 지역

제4장 경쟁

JHS 24.09.27

Global Male Hypogonadism Market to Reach US$6.1 Billion by 2030

The global market for Male Hypogonadism estimated at US$4.3 Billion in the year 2023, is expected to reach US$6.1 Billion by 2030, growing at a CAGR of 5.0% over the analysis period 2023-2030. Testosterone Replacement Therapy, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$3.5 Billion by the end of the analysis period. Growth in the Gonadotropin & Gonadotropin Releasing Hormones Therapy segment is estimated at 5.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 4.8% CAGR

The Male Hypogonadism market in the U.S. is estimated at US$1.2 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$962.5 Million by the year 2030 trailing a CAGR of 4.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.5% and 4.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global Male Hypogonadism Market - Key Trends & Drivers Summarized

What Is Male Hypogonadism and Why Is Early Diagnosis Important?

Male hypogonadism is a medical condition characterized by low testosterone levels, leading to a range of symptoms such as reduced libido, fatigue, muscle loss, and mood disturbances. This condition can result from aging, genetic factors, or medical conditions that affect the testes or pituitary gland. Early diagnosis of male hypogonadism is essential for managing symptoms and preventing long-term complications such as osteoporosis, cardiovascular disease, and infertility. With the global aging population and increased awareness of hormonal imbalances in men, the demand for effective treatments and diagnostic tools has risen substantially, highlighting the importance of early detection and proper management of hypogonadism.

How Are Advances in Hormone Replacement Therapy Shaping Male Hypogonadism Treatment?

The treatment of male hypogonadism has advanced significantly with the development of hormone replacement therapies (HRT) that restore testosterone levels to a healthy range. Testosterone replacement therapy (TRT), available in various forms such as gels, injections, and patches, has become the cornerstone of treatment for hypogonadism. These therapies not only alleviate symptoms but also help reduce the risk of long-term health issues associated with testosterone deficiency. Newer, long-acting formulations that require less frequent administration are gaining popularity due to their convenience and ability to maintain stable testosterone levels. Additionally, advancements in personalized medicine are enabling healthcare providers to tailor treatments to individual needs, improving patient outcomes and satisfaction.

What Challenges Exist in Managing Male Hypogonadism?

Managing male hypogonadism presents several challenges, particularly in ensuring that patients receive appropriate and timely treatment. One challenge is the underdiagnosis of the condition, as many men may attribute symptoms of testosterone deficiency to aging and fail to seek medical attention. Moreover, the potential side effects of long-term testosterone therapy, such as increased risk of cardiovascular events and prostate issues, have raised concerns among both patients and clinicians. These risks necessitate careful monitoring and individualized treatment plans. Another challenge lies in access to care, as testosterone replacement therapies can be costly, and insurance coverage may vary. Additionally, adherence to therapy remains a concern, particularly with the need for regular administration of treatments.

Growth in the Male Hypogonadism Market Is Driven by Several Factors

The growth in the male hypogonadism market is driven by several factors, including the rising prevalence of the condition due to aging populations, increased awareness of hormonal health in men, and advancements in testosterone replacement therapies. As diagnostic tools improve, more men are being diagnosed earlier, leading to greater demand for effective treatments. Technological innovations in drug delivery systems, such as long-acting injectables and transdermal patches, are enhancing patient compliance and outcomes. Furthermore, the growing focus on men’s health and the increasing availability of telemedicine services are making it easier for patients to seek diagnosis and treatment, contributing to the market's expansion.

Select Competitors (Total 47 Featured) -

  • Bayer AG
  • TesoRx Pharma LLC

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Male Hypogonadism - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Testosterone Deficiency Drives Growth in Male Hypogonadism Market
    • Technological Advancements in Hormone Replacement Therapies Propel Adoption
    • Growing Awareness of Male Hormonal Health Expands Addressable Market for Hypogonadism Treatments
    • Increased Focus on Mens Health Issues Strengthens Business Case for Hypogonadism Diagnosis
    • Rising Demand for Non-invasive Treatments Spurs Growth in Alternative Therapy Solutions
    • Technological Innovations in Testosterone Delivery Systems Accelerate Market Growth
    • Growing Use of Telemedicine Platforms Expands Access to Male Hypogonadism Treatment
    • Increasing Availability of Personalized Medicine Options Drives Adoption of Targeted Therapies
    • Improved Diagnostic Tools for Hormonal Imbalance Propel Demand for Early Detection
    • Rising Focus on Patient-centric Treatment Models Expands Opportunities for Customized Care
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Male Hypogonadism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Male Hypogonadism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Male Hypogonadism by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Testosterone Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Testosterone Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Testosterone Replacement Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Gonadotropin & Gonadotropin Releasing Hormones Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Gonadotropin & Gonadotropin Releasing Hormones Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Gonadotropin & Gonadotropin Releasing Hormones Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 10: World Male Hypogonadism Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Topical Gels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Topical Gels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Topical Gels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Injectables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Transdermal Patches by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Transdermal Patches by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Transdermal Patches by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Drug Delivery Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Drug Delivery Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Drug Delivery Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Pituitary Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Pituitary Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Pituitary Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Klinefelters Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Klinefelters Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Klinefelters Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Kallmann Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Kallmann Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Kallmann Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Other Disorder Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Other Disorder Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for Other Disorder Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Male Hypogonadism Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2014, 2024 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Male Hypogonadism by Drug Delivery Type - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types for the Years 2014, 2024 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Male Hypogonadism by Disorder Type - Percentage Breakdown of Value Sales for Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2014, 2024 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Male Hypogonadism by Drug Delivery Type - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types for the Years 2014, 2024 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Male Hypogonadism by Disorder Type - Percentage Breakdown of Value Sales for Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types for the Years 2014, 2024 & 2030
  • JAPAN
    • Male Hypogonadism Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2014, 2024 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Male Hypogonadism by Drug Delivery Type - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types for the Years 2014, 2024 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Male Hypogonadism by Disorder Type - Percentage Breakdown of Value Sales for Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types for the Years 2014, 2024 & 2030
  • CHINA
    • Male Hypogonadism Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 62: China Recent Past, Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: China 16-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2014, 2024 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: China 16-Year Perspective for Male Hypogonadism by Drug Delivery Type - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types for the Years 2014, 2024 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: China 16-Year Perspective for Male Hypogonadism by Disorder Type - Percentage Breakdown of Value Sales for Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types for the Years 2014, 2024 & 2030
  • EUROPE
    • Male Hypogonadism Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Male Hypogonadism by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Male Hypogonadism by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Male Hypogonadism by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2014, 2024 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Male Hypogonadism by Drug Delivery Type - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types for the Years 2014, 2024 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Male Hypogonadism by Disorder Type - Percentage Breakdown of Value Sales for Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types for the Years 2014, 2024 & 2030
  • FRANCE
    • Male Hypogonadism Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 83: France Recent Past, Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: France 16-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2014, 2024 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: France 16-Year Perspective for Male Hypogonadism by Drug Delivery Type - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types for the Years 2014, 2024 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: France 16-Year Perspective for Male Hypogonadism by Disorder Type - Percentage Breakdown of Value Sales for Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types for the Years 2014, 2024 & 2030
  • GERMANY
    • Male Hypogonadism Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2014, 2024 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Male Hypogonadism by Drug Delivery Type - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types for the Years 2014, 2024 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Male Hypogonadism by Disorder Type - Percentage Breakdown of Value Sales for Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2014, 2024 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Male Hypogonadism by Drug Delivery Type - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types for the Years 2014, 2024 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Male Hypogonadism by Disorder Type - Percentage Breakdown of Value Sales for Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Male Hypogonadism Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 110: UK Recent Past, Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2014, 2024 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Male Hypogonadism by Drug Delivery Type - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types for the Years 2014, 2024 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Male Hypogonadism by Disorder Type - Percentage Breakdown of Value Sales for Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Rest of Europe Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Rest of Europe 16-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2014, 2024 & 2030
    • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Rest of Europe Historic Review for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Rest of Europe 16-Year Perspective for Male Hypogonadism by Drug Delivery Type - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types for the Years 2014, 2024 & 2030
    • TABLE 125: Rest of Europe Recent Past, Current & Future Analysis for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Rest of Europe Historic Review for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Rest of Europe 16-Year Perspective for Male Hypogonadism by Disorder Type - Percentage Breakdown of Value Sales for Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Male Hypogonadism Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Asia-Pacific 16-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2014, 2024 & 2030
    • TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Asia-Pacific Historic Review for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Asia-Pacific 16-Year Perspective for Male Hypogonadism by Drug Delivery Type - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types for the Years 2014, 2024 & 2030
    • TABLE 134: Asia-Pacific Recent Past, Current & Future Analysis for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Asia-Pacific Historic Review for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Asia-Pacific 16-Year Perspective for Male Hypogonadism by Disorder Type - Percentage Breakdown of Value Sales for Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 137: Rest of World Recent Past, Current & Future Analysis for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of World Historic Review for Male Hypogonadism by Therapy - Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of World 16-Year Perspective for Male Hypogonadism by Therapy - Percentage Breakdown of Value Sales for Testosterone Replacement Therapy and Gonadotropin & Gonadotropin Releasing Hormones Therapy for the Years 2014, 2024 & 2030
    • TABLE 140: Rest of World Recent Past, Current & Future Analysis for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of World Historic Review for Male Hypogonadism by Drug Delivery Type - Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of World 16-Year Perspective for Male Hypogonadism by Drug Delivery Type - Percentage Breakdown of Value Sales for Topical Gels, Injectables, Transdermal Patches and Other Drug Delivery Types for the Years 2014, 2024 & 2030
    • TABLE 143: Rest of World Recent Past, Current & Future Analysis for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Rest of World Historic Review for Male Hypogonadism by Disorder Type - Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Rest of World 16-Year Perspective for Male Hypogonadism by Disorder Type - Percentage Breakdown of Value Sales for Pituitary Disorders, Klinefelters Syndrome, Kallmann Syndrome and Other Disorder Types for the Years 2014, 2024 & 2030

IV. COMPETITION

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제